REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – MS is generally described as a disease that primarily affects Caucasians, however, a new study from southern California suggests that the incidence is higher in African Americans than in other racial/ethnic groups (Langer-Gould et al. AAN 2011; abstract P06.032).
Latest News
Comorbidities common, delay MS diagnosis
April 15, 2011REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – The U.S. National Health and Wellness Survey, an annual internet survey of health behaviours, reports that people with MS more commonly report comorbidities compared to those in the general population (Meletiche et al. AAN 2011; abstract P06.045).
Fingolimod: disease-free rates and effect on brain atrophy
April 15, 2011REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – Two analyses of data from the phase III FREEDOMS trial report that fingolimod increases the proportion of MS patients who are disease-free and reduces brain atrophy compared to placebo.
Cholesterol levels may adversely affect MS disease progression
April 14, 2011REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – A retrospective study of 491 MS patients reports that the serum lipid profile may adversely affect disease progression in MS patients (Weinstock-Guttman et al. AAN 2011; abstract P04.235). The chart review compared the results of lipid profile testing, MRI findings and EDSS scores at baseline and after >6 months’ follow-up.